461 completed. 461 Phase 1, 124 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 461 | Completed 461 |
| Phase 2 | 124 | Completed 124 |
Follow Leukemia, B-Cell: new trials by email Literature Review of Leukemia, B-Cell trials Research Report on Leukemia, B-Cell
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Clinical Study Aiming to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of a Single Administration of ZE50-0134 at 5 Dose Levels in Healthy Volunteers ZE50-0134 or placebo, Rabeprazole 20 mg, Itraconazole (200 mg) - Healthy | Phase 1 | Completed | Lomond Therapeutics Holdings, Inc. | 104 | 2024-05-21 | 2025-12-05 |
| A Study of PRT2527 as Monotherapy and in Combination With Zanubrutinib or Venetoclax in Participants With R/R Hematologic Malignancies PRT2527, Zanubrutinib, Venetoclax - Aggressive B-Cell Non-Hodgkin's Lymphoma (NHL), Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) | Phase 1 | Completed | Prelude Therapeutics Incorporated | 86 | 2023-09-12 | 2026-01-26 |
| Dose Escalation/Dose Expansion Study of PRGN-3007 UltraCAR-T Cells in Patients With Advanced Hematologic and Solid Tumor Malignancies Fludarabine, Cyclophosphamide, PRGN-3007 - Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma | Phase 1 | Completed | H. Lee Moffitt Cancer Center and Research Institute | 3 | 2023-01-25 | 2026-02-06 |
| Study of Oral LOXO-338 in Patients With Advanced Blood Cancers LOXO-338, Pirtobrutinib - Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-cell Marginal Zone | Phase 1 | Completed | Eli Lilly and Company | 27 | 2021-09-30 | 2026-10-06 |
| Rituximab + High-Dose Methylprednisolone Debulking Prior to Venetoclax for CLL & SLL Patients HDMP + rituximab as a means of debulking prior to initiating venetoclax. - Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | Phase 1 | Completed | University of California, San Diego | 4 | 2021-09-02 | 2026-08-20 |
| A Study of the MALT1 Inhibitor JNJ-67856633 and Ibrutinib in Combination in B-cell NHL and CLL JNJ-67856633, Ibrutinib - Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Non-Hodgkin | Phase 1 | Completed | Janssen Research & Development, LLC | 45 | 2021-07-28 | 2025-08-21 |
| A Study of JNJ-64264681 and JNJ-67856633 in Participants With Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia JNJ-64264681, JNJ-67856633 - Lymphoma, Non-Hodgkin, Chronic Lymphocytic Leukemia | Phase 1 | Completed | Janssen Research & Development, LLC | 75 | 2021-02-25 | 2025-08-21 |
| Intermittent Fasting and CLL/SLL Intermittent fast - Neoplasms, Leukemia, Lymphocytic, Chronic | Phase 1 | Completed | Eleah Stringer | 15 | 2021-02-03 | 2023-02-14 |
| Long-term Follow-up Study for Patients Treated With CLBR001 CAR-T CLBR001 and SWI019 - Relapsed/Refractory B-cell Lymphomas, Diffuse Large B-Cell Lymphoma (DLBCL) | Phase 1 | Completed | Calibr, a division of Scripps Research | 16 | 2021-01-21 | 2026-04-08 |
| Personalized Multi-peptide Vaccination in CLL Patients Multipeptide Vaccine+ XS15 - Chronic Lymphocytic Leukemia | Phase 1 | Completed | University Hospital Tuebingen | 20 | 2020-12-23 | 2024-12-09 |
| A Safety and Preliminary Efficacy Study of CC-99282 in Combination With Obinutuzumab in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma CC-99282, Obinutuzumab - Lymphoma, Non-Hodgkin | Phase 1 | Completed | Celgene | 16 | 2020-12-21 | 2024-07-25 |
| Pitavastatin in Combination With Venetoclax for Chronic Lymphocytic Leukemia or Acute Myeloid Leukemia Pitavastatin, Venetoclax - Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia | Phase 1 | Completed | University of California, Irvine | 6 | 2020-12-02 | 2025-09-11 |
| A Study of JNJ-75348780 in Participants With Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL) JNJ-75348780 - Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell | Phase 1 | Completed | Janssen Research & Development, LLC | 147 | 2020-11-20 | 2025-10-10 |
| CC-486, Lenalidomide, and Obinutuzumab for the Treatment of Recurrent or Refractory CD20 Positive B-cell Lymphoma Lenalidomide, Obinutuzumab, Oral Azacitidine - Indolent B-Cell Non-Hodgkin Lymphoma, Recurrent B-Cell Non-Hodgkin Lymphoma | Phase 1 | Completed | Joseph Tuscano | 8 | 2020-10-23 | 2025-04-24 |
| CLBR001 and SWI019 in Patients With Relapsed / Refractory B-cell Malignancies CLBR001 and SWI019 - Relapsed/Refractory B-cell Lymphomas, Diffuse Large B Cell Lymphoma (DLBCL) | Phase 1 | Completed | Calibr, a division of Scripps Research | 18 | 2020-08-14 | 2024-08-20 |
| A Study of JNJ-64264681 in Participants With Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia JNJ-64264681 - Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell | Phase 1 | Completed | Janssen Research & Development, LLC | 85 | 2020-07-02 | 2025-08-21 |
| A Phase Ib Study of YY-20394 in Participants With B-cell Hematologic Malignancies YY-20394 - Small Lymphocytic Lymphoma, Lymphoplasmacytic Lymphoma | Phase 1 | Completed | Shanghai YingLi Pharmaceutical Co. Ltd. | 43 | 2020-06-15 | 2024-06-13 |
| Study of BGB-10188 as Monotherapy, and in Combination With Zanubrutinib, and Tislelizumab BGB-10188, Zanubrutinib, Tislelizumab - Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | Phase 1 / Phase 2 | Completed | BeiGene | 97 | 2020-04-29 | 2026-02-20 |
| BR101801 in Adult Patients With Advanced Hematologic Malignancies(Phase I) BR101801 (Phase Ia), BR101801 (Phase Ib) - Diffuse Large B Cell Lymphoma, Follicular Lymphoma | Phase 1 | Completed | Boryung Pharmaceutical Co., Ltd | 26 | 2020-04-21 | 2025-09-10 |
| Dose-escalation Study of Safety of PBCAR20A in Subjects With r/r NHL or r/r CLL/SLL PBCAR20A, Fludarabine, Cyclophosphamide - Non-Hodgkin's Lymphoma, Relapsed, Chronic Lymphoid Leukemia in Relapse | Phase 1 / Phase 2 | Completed | Precision BioSciences, Inc. | 18 | 2020-03-24 | 2023-01-31 |
Showing 20 of 461. Sign in to see all of them.
Leukemia, Lymphocytic, Chronic, B-Cell (444) · Lymphoma, Non-Hodgkin (228) · Lymphoma, Mantle-Cell (210) · Lymphoma, Follicular (209) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (197) · Lymphoma, B-Cell, Marginal Zone (193) · Lymphoma, Large B-Cell, Diffuse (179) · Lymphoma (160) · Burkitt Lymphoma (154) · Hodgkin Disease (143) · Lymphoma, Large-Cell, Immunoblastic (142) · Leukemia (132) · Waldenstrom Macroglobulinemia (105) · Leukemia, Myeloid, Acute (102) · Multiple Myeloma (99)
Hemic and Lymphatic Diseases (461) · Neoplasms by Histologic Type (461) · Immunoproliferative Disorders (459) · Lymphatic Diseases (458) · Hematologic Diseases (457) · Leukemia, Lymphoid (457) · Immune System Diseases (456) · Lymphoproliferative Disorders (454) · Pathologic Processes (446) · Pathological Conditions, Signs and Symptoms (446) · Chronic Disease (445) · Disease Attributes (445) · Neoplasms (430) · Leukemia (329)
Rituximab (69) · fludarabine phosphate (47) · Cyclophosphamide (40) · Lenalidomide (25) · Peripheral Blood Stem Cell Transplantation (24) · fludarabine (23) · Bendamustine Hydrochloride (22) · Filgrastim (21) · ibrutinib (21) · Bortezomib (16) · Etoposide (13) · Melphalan (13) · Mycophenolic Acid (13) · Tacrolimus (13) · Antilymphocyte Serum (11)
National Cancer Institute (NCI) (64) · M.D. Anderson Cancer Center (27) · Fred Hutchinson Cancer Center (17) · Memorial Sloan Kettering Cancer Center (12) · National Institutes of Health Clinical Center (CC) (11) · Mayo Clinic (10) · Gilead Sciences (8) · Celgene (7) · Janssen Research & Development, LLC (7) · National Heart, Lung, and Blood Institute (NHLBI) (7) · Pharmacyclics LLC. (7) · Dana-Farber Cancer Institute (6) · Genentech, Inc. (6) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (6) · TG Therapeutics, Inc. (6)
United States (401) · Canada (25) · Germany (25) · United Kingdom (24) · France (22) · Australia (16) · Spain (15) · Italy (14) · South Korea (12) · Poland (11) · Japan (8) · Austria (7) · China (7) · Netherlands (6) · Israel (5)
Shivaani Kummar, MD (5) · Mario Sznol, MD (4) · Scott Stromatt, MD (4) · Brenda Sandmaier (3) · Edward A. Sausville, MD, PhD (3) · Jennifer Woyach, MD (3) · John Byrd (3) · Steven Grant, MD (3) · Thomas C. Shea, MD (3)
PMID 34515338, PMID 32499241, PMID 34398557, PMID 19238148, PMID 19949018, PMID 20028764, PMID 20882050, PMID 21816833, PMID 22002018, PMID 23886836, PMID 24055823, PMID 25317870, PMID 25381051, PMID 26182309, PMID 26813675, PMID 27482888, PMID 31023700, PMID 34780125, PMID 10552943, PMID 10764422, PMID 11410496, PMID 11756154, PMID 12114413, PMID 12171484, PMID 14630685, PMID 14767498, PMID 15013589, PMID 15466934, PMID 15570084, PMID 16051743, PMID 16061911, PMID 16135477, PMID 16186597, PMID 16731764, PMID 17020988, PMID 17119113, PMID 17312328, PMID 17640728, PMID 17679729, PMID 17947483, PMID 18327587, PMID 18418404, PMID 18463792, PMID 18470481, PMID 18509084, PMID 18824593, PMID 18931344, PMID 18974373, PMID 19179301, PMID 19225537
U01CA076576 (10), P30CA015704 (7), P30CA016058 (6), U01CA069912 (6), P30CA006973 (5), P30CA015083 (5), U01CA062502 (5), U01CA062505 (5), U01CA070095 (5), U01CA099168 (5), 2015 (4), U01CA062487 (4), U01CA062491 (4), 2009 (3), P30CA008748 (3)